Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma

Sonoma Pharmaceuticals, Inc.

EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.
Termination effective November 21, 2024; no penalties incurred by Sonoma.
Sonoma resumes direct U.S. sales of Microcyn-based products: Acuicyn, Celacyn, Epicyn, Lasercyn, Levicyn.
Agreement had a five-year initial term; exclusive distribution rights now ended.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.